KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Liabilities (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Total Liabilities data on record, last reported at $7.4 billion in Q3 2025.

  • For Q3 2025, Total Liabilities fell 8.5% year-over-year to $7.4 billion; the TTM value through Sep 2025 reached $7.4 billion, down 8.5%, while the annual FY2024 figure was $7.9 billion, 3.42% up from the prior year.
  • Total Liabilities reached $7.4 billion in Q3 2025 per JAZZ's latest filing, up from $7.2 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $9.1 billion in Q2 2021 and bottomed at -$3.8 billion in Q2 2024.
  • Average Total Liabilities over 5 years is $5.8 billion, with a median of $7.7 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: crashed 221.96% in 2022, then skyrocketed 341.66% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $8.3 billion in 2021, then decreased by 7.01% to $7.7 billion in 2022, then decreased by 1.2% to $7.7 billion in 2023, then rose by 3.42% to $7.9 billion in 2024, then fell by 6.58% to $7.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $7.4 billion in Q3 2025, $7.2 billion in Q2 2025, and $7.4 billion in Q1 2025.